Referred to as Ad5-nCoV, the vaccine candidate received Chinese regulatory approval earlier this year, allowing CanSino Biologics to move ahead with human clinical trials in China.
This advertisement has not loaded yet, but your article continues below.
But, there can be problems too; these vaccines require two doses to be administered, while a small minority of patients can suffer chronic reactions to such vaccines and even develop the disease, something that the CanSino vaccine is less prone to induce.
In February 2021, Mexico approved the vaccine for emergency use.
Because trials in Argentina found that a second shot of Moderna after the first Sputnik shot was superior to 2-shot Sputnik V.
In July, 2021, Cansino said it would begin combination trials with a dose of followed by a dose of Convidecia.